Discovering Opportunities in Low-Priced Stocks
As inflation continues to plague American households following the disruptions caused by the Covid-19 pandemic, investors are turning their sights towards stocks priced below $20 in a bid to outmaneuver soaring prices. Despite their modest price tags, these stocks harbor potential for substantial growth.
Accessibility plays a crucial role in the popularity of low-priced equities, with not every brokerage offering fractional share ownership. The simplicity of owning whole units of stocks from a psychological standpoint cannot be understated – after all, the math is much easier.
Stocks priced under $20 occupy a unique position in the market ecosystem. Positioned as viable enterprises with room for growth, these hidden gems are often overshadowed, presenting an opportunity for investors to capitalize on undervalued assets that could experience a dramatic upswing in sentiment.
Investing in the sub-$20 stock category comes with a higher risk-but-reward ratio. Those willing to navigate this high-risk domain may find these affordable stocks promising for their portfolio.
Genius Sports: A Smart Bet
Breaking Down Viridian Therapeutics’ Potential Growth
Source: PopTika / Shutterstock.com
A biotechnology company, Viridian Therapeutics (NASDAQ:VRDN) is on a mission to discover and develop treatments for serious and rare diseases. One of its stellar products, VRDN-001, a monoclonal antibody currently undergoing Phase 3 trials, is tailored for the treatment of thyroid eye disease. Despite experiencing a rollercoaster ride in the stock market, with a decline of over 22% since January, hope still glimmers on the horizon for daring investors.
Analyzing Earnings Trends
Viridian’s financial performance, while not without its share of bumps, does carry a glint of promise. In the third quarter of last year, the company’s loss per share stood at $1.09, surpassing the anticipated loss of $1.27. It also marginally outperformed in the second quarter, logging a loss of $1.27 against an expected $1.29. Yet, the average earnings surprise for the first and fourth quarters was a staggering 46.4% below expectations.
Upside Potential in Sales
This year poses a conundrum, with sales estimated to hit $270,000, a drop from the previous year’s revenue of $314,000. Despite this, projections hint at a meteoric rise in revenue by 2025, possibly touching $8.3 million. Such forecasts hint at a promising trajectory for the company.
Analysts’ Enthusiasm
Standing on the threshold of potential, analysts view VRDN with unwavering interest, bestowing it with a unanimous strong buy rating and a target price of $38.64. Such a forecast heralds a potential upside of nearly 123%, positioning Viridian as one of the standout stocks priced under $20.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
